D. Turnquist

A Randomized Phase I Evaluation of CTP‐499, a Novel Deuterium‐Containing Drug Candidate for Diabetic Nephropathy

M. Harnett, L. Sabounjian, V. Braman, 2013, Clinical pharmacology in drug development.

Design of BET Inhibitor Bottlebrush Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities.

Jeremiah A. Johnson, Matthew R. Golder, M. Shipitsin, 2021, Journal of the American Chemical Society.

Design of BET Inhibitor Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities

Matthew R. Golder, M. Shipitsin, B. Vangamudi, 2020 .

Successful therapy of metastatic embryonal carcinoma coexisting with gonadoblastoma in a patient with 46,XY pure gonadal dysgenesis (Swyer's syndrome).

S. Nicosia, J. Lapolla, D. Cavanagh, 1990, Gynecologic oncology.

Design and Rationale for Randomized, Doubleblind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Patients With Diabetic Nephropathy (DN)

Lijun Wu, M. Harnett, L. Sabounjian, 2012 .

Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men

R. Thieroff-Ekerdt, D. Corzo, M. Boyce, 2020, Journal of Clinical Endocrinology and Metabolism.